{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T13:15:34Z","timestamp":1790946934986,"version":"4.1.0"},"reference-count":36,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","heartandlung.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Heart &amp; Lung"],"published-print":{"date-parts":[[2026,7]]},"DOI":"10.1016\/j.hrtlng.2026.102739","type":"journal-article","created":{"date-parts":[[2026,2,23]],"date-time":"2026-02-23T11:58:02Z","timestamp":1771847882000},"page":"102739","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":5,"special_numbering":"C","title":["Factor XI inhibitors versus direct oral anticoagulants for the prevention of thromboembolic events and safety in patients with atrial fibrillation: A systematic review and meta-analysis of randomized controlled trials"],"prefix":"10.1016","volume":"78","author":[{"ORCID":"https:\/\/orcid.org\/0009-0002-4998-8075","authenticated-orcid":false,"given":"Jo\u00e3o Pedro Toledo Lima","family":"de Alc\u00e2ntara","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"George Willian Xavier da Rosa","family":"G\u00f6tz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pedro Enrique Ortiz","family":"Amaral","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guilherme","family":"Cecchetti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gustavo Lenci","family":"Marques","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"5","key":"10.1016\/j.hrtlng.2026.102739_bib0001","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1093\/eurheartj\/ehaa612","volume":"42","author":"Hindricks","year":"2021","journal-title":"Eur Heart J"},{"key":"10.1016\/j.hrtlng.2026.102739_bib0002","doi-asserted-by":"crossref","DOI":"10.3389\/fcvm.2023.1151575","article-title":"Prevalence and trend of atrial fibrillation and its associated risk factors among the population from nationwide health check-up centers in China, 2012-2017","volume":"10","author":"Sun","year":"2023","journal-title":"Front Cardiovasc Med"},{"issue":"8","key":"10.1016\/j.hrtlng.2026.102739_bib0003","doi-asserted-by":"crossref","first-page":"983","DOI":"10.1161\/01.STR.22.8.983","article-title":"Atrial fibrillation as an independent risk factor for stroke: the Framingham Study","volume":"22","author":"Wolf","year":"1991","journal-title":"Stroke"},{"issue":"6","key":"10.1016\/j.hrtlng.2026.102739_bib0004","doi-asserted-by":"crossref","first-page":"1115","DOI":"10.1161\/01.STR.0000166053.83476.4a","article-title":"Contribution of atrial fibrillation to incidence and outcome of ischemic stroke: results from a population-based study","volume":"36","author":"Marini","year":"2005","journal-title":"Stroke"},{"key":"10.1016\/j.hrtlng.2026.102739_bib0005","doi-asserted-by":"crossref","first-page":"i4482","DOI":"10.1136\/bmj.i4482","article-title":"Atrial fibrillation and risks of cardiovascular disease, renal disease, and death: systematic review and meta-analysis","volume":"354","author":"Odutayo","year":"2016","journal-title":"BMJ"},{"issue":"1","key":"10.1016\/j.hrtlng.2026.102739_bib0006","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1016\/j.jacc.2019.01.011","volume":"74","author":"January","year":"2019","journal-title":"J Am Coll Cardiol"},{"issue":"36","key":"10.1016\/j.hrtlng.2026.102739_bib0007","doi-asserted-by":"crossref","first-page":"3599","DOI":"10.1093\/eurheartj\/ehab368","article-title":"2021 ESC guidelines for the diagnosis and treatment of acute and chronic heart failure","volume":"42","author":"McDonagh","year":"2021","journal-title":"Eur Heart J"},{"issue":"10","key":"10.1016\/j.hrtlng.2026.102739_bib0008","first-page":"e89","article-title":"2018 Korean Guideline of Atrial fibrillation management","volume":"48","author":"Joung","year":"2018","journal-title":"Korean Circ J"},{"issue":"9921","key":"10.1016\/j.hrtlng.2026.102739_bib0009","doi-asserted-by":"crossref","first-page":"955","DOI":"10.1016\/S0140-6736(13)62343-0","article-title":"Comparison of the efficacy and safety of new oral anticoagulants with warfarin in patients with atrial fibrillation: a meta-analysis of randomised trials","volume":"383","author":"Ruff","year":"2014","journal-title":"Lancet"},{"issue":"8","key":"10.1016\/j.hrtlng.2026.102739_bib0010","first-page":"888","article-title":"New oral anticoagulants in patients with nonvalvular atrial fibrillation: a meta-analysis","volume":"30","author":"Sardar","year":"2014","journal-title":"Can J Cardiol"},{"issue":"12","key":"10.1016\/j.hrtlng.2026.102739_bib0011","first-page":"2359","article-title":"Bleeding risk assessment in atrial fibrillation: observations on the use and misuse of bleeding risk scores","volume":"14","author":"Lip","year":"2016","journal-title":"J Thromb Haemost"},{"issue":"1","key":"10.1016\/j.hrtlng.2026.102739_bib0012","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1001\/jamacardio.2015.0374","article-title":"Oral anticoagulant therapy prescription in patients with atrial fibrillation across the spectrum of stroke risk: insights from the NCDR PINNACLE Registry","volume":"1","author":"Hsu","year":"2016","journal-title":"JAMA Cardiol"},{"key":"10.1016\/j.hrtlng.2026.102739_bib0013","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1016\/j.ahj.2017.08.011","article-title":"International trends in clinical characteristics and oral anticoagulation treatment for patients with atrial fibrillation: results from the GARFIELD-AF, ORBIT-AF I, and ORBIT-AF II registries","volume":"194","author":"Steinberg","year":"2017","journal-title":"Am Heart J"},{"issue":"5031","key":"10.1016\/j.hrtlng.2026.102739_bib0014","first-page":"538","article-title":"Factor XI activation in a revised model of blood coagulation","volume":"254","author":"Gailani","year":"1991","journal-title":"Science"},{"key":"10.1016\/j.hrtlng.2026.102739_bib0015","first-page":"71","article-title":"The hemostatic role of factor XI","volume":"146","author":"Puy","year":"2016","journal-title":"Thromb Res"},{"issue":"7","key":"10.1016\/j.hrtlng.2026.102739_bib0016","first-page":"1497","article-title":"Single nucleotide polymorphisms in the promoter region of the factor XI gene are associated with venous thrombosis","volume":"1","author":"Salomon","year":"2003","journal-title":"J Thromb Haemost"},{"issue":"12","key":"10.1016\/j.hrtlng.2026.102739_bib0017","first-page":"1710","article-title":"Factor XI deficiency is associated with lower risk for cardiovascular and venous thromboembolism events","volume":"129","author":"Preis","year":"2017","journal-title":"Blood."},{"issue":"6","key":"10.1016\/j.hrtlng.2026.102739_bib0018","first-page":"651","article-title":"Factor XI deficiency","volume":"36","author":"G\u00f3mez","year":"2010","journal-title":"Semin Thromb Hemost"},{"issue":"5","key":"10.1016\/j.hrtlng.2026.102739_bib0019","first-page":"387","article-title":"Factor XI as a target for new anticoagulants","volume":"24","author":"Weitz","year":"2017","journal-title":"Curr Opin Hematol"},{"issue":"1","key":"10.1016\/j.hrtlng.2026.102739_bib0020","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1111\/jth.15126","article-title":"New anticoagulants: moving beyond the direct oral anticoagulants","volume":"19","author":"Fredenburgh","year":"2021","journal-title":"J Thromb Haemost"},{"issue":"4","key":"10.1016\/j.hrtlng.2026.102739_bib0021","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1056\/NEJMoa1405760","article-title":"Factor XI antisense oligonucleotide for prevention of venous thrombosis","volume":"372","author":"B\u00fcller","year":"2015","journal-title":"N Engl J Med"},{"issue":"1","key":"10.1016\/j.hrtlng.2026.102739_bib0022","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1001\/jama.2019.20687","article-title":"Effect of Osocimab in preventing venous thromboembolism among patients undergoing knee arthroplasty: the FOXTROT randomized clinical trial","volume":"323","author":"Weitz","year":"2020","journal-title":"JAMA"},{"issue":"6","key":"10.1016\/j.hrtlng.2026.102739_bib0023","first-page":"436","article-title":"Randomized, parallel-group, dose-ranging study of the factor XIa inhibitor asundexian to prevent stroke in patients with nonvalvular atrial fibrillation (PACIFIC-AF)","volume":"145","author":"Piccini","year":"2022","journal-title":"Circulation"},{"key":"10.1016\/j.hrtlng.2026.102739_bib0024","first-page":"12","article-title":"Abelacimab versus Rivaroxaban in patients with atrial fibrillation (AZALEA-TIMI 71)","volume":"392","author":"Christian","year":"2025","journal-title":"N Engl J Med"},{"issue":"1","key":"10.1016\/j.hrtlng.2026.102739_bib0025","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1056\/NEJMoa2407105","article-title":"Asundexian versus Apixaban in patients with atrial fibrillation","volume":"392","author":"Piccini","year":"2025","journal-title":"N Engl J Med"},{"key":"10.1016\/j.hrtlng.2026.102739_bib0026","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1016\/j.ahj.2024.08.011","article-title":"Milvexian vs apixaban for stroke prevention in atrial fibrillation: the LIBREXIA atrial fibrillation trial rationale and design","volume":"277","author":"Jain","year":"2024","journal-title":"Am Heart J"},{"key":"10.1016\/j.hrtlng.2026.102739_bib0027","doi-asserted-by":"crossref","unstructured":"Haddaway, N.R., Page, M.J., Pritchard, C.C., & McGuinness, L.A. (2022). PRISMA2020: an R package and Shiny app for producing PRISMA 2020-compliant flow diagrams, with interactivity for optimised digital transparency and Open Synthesis Campbell Systematic Reviews, 18, e1230. doi:10.1002\/cl2.1230.","DOI":"10.1002\/cl2.1230"},{"key":"10.1016\/j.hrtlng.2026.102739_bib0028","doi-asserted-by":"crossref","first-page":"l4898","DOI":"10.1136\/bmj.l4898","article-title":"RoB 2: a revised tool for assessing risk of bias in randomised trials","volume":"366","author":"Sterne","year":"2019","journal-title":"BMJ"},{"issue":"4","key":"10.1016\/j.hrtlng.2026.102739_bib0029","doi-asserted-by":"crossref","first-page":"692","DOI":"10.1111\/j.1538-7836.2005.01204.x","volume":"3","author":"Schulman","year":"2005","journal-title":"J Thromb Haemost."},{"issue":"3","key":"10.1016\/j.hrtlng.2026.102739_bib0030","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1016\/0197-2456(86)90046-2","article-title":"Meta-analysis in clinical trials","volume":"7","author":"DerSimonian","year":"1986","journal-title":"Control Clin Trials"},{"issue":"11","key":"10.1016\/j.hrtlng.2026.102739_bib0031","doi-asserted-by":"crossref","first-page":"1539","DOI":"10.1002\/sim.1186","article-title":"Quantifying heterogeneity in a meta-analysis","volume":"21","author":"Higgins","year":"2002","journal-title":"Stat Med"},{"issue":"6","key":"10.1016\/j.hrtlng.2026.102739_bib0032","doi-asserted-by":"crossref","first-page":"840","DOI":"10.1002\/jrsm.1460","article-title":"Zero-cell corrections in random-effects meta-analyses","volume":"11","author":"Weber","year":"2020","journal-title":"Res Synth Methods"},{"issue":"7109","key":"10.1016\/j.hrtlng.2026.102739_bib0033","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1136\/bmj.315.7109.629","article-title":"Bias in meta-analysis detected by a simple, graphical test","volume":"315","author":"Egger","year":"1997","journal-title":"BMJ"},{"key":"10.1016\/j.hrtlng.2026.102739_bib0034","unstructured":"R Core Team. R: a language and environment for statistical computing. Vienna, Austria: R Foundation for Statistical Computing. 2024. URL https:\/\/www.R-project.org\/."},{"key":"10.1016\/j.hrtlng.2026.102739_bib0035","unstructured":"Schwarzer G., Carpenter J.R., R\u00fccker G. meta: general package for meta-analysis. R package version 4.5.0. 2024. URL https:\/\/CRAN.R-project.org\/package=meta."},{"issue":"3","key":"10.1016\/j.hrtlng.2026.102739_bib0036","doi-asserted-by":"crossref","first-page":"1","DOI":"10.18637\/jss.v036.i03","article-title":"Conducting meta-analyses in R with the metafor package","volume":"36","author":"Viechtbauer","year":"2010","journal-title":"J Stat Softw"}],"container-title":["Heart &amp; Lung"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0147956326000166?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0147956326000166?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,7,21]],"date-time":"2026-07-21T20:42:20Z","timestamp":1784666540000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0147956326000166"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7]]},"references-count":36,"alternative-id":["S0147956326000166"],"URL":"https:\/\/doi.org\/10.1016\/j.hrtlng.2026.102739","relation":{},"ISSN":["0147-9563"],"issn-type":[{"value":"0147-9563","type":"print"}],"subject":[],"published":{"date-parts":[[2026,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Factor XI inhibitors versus direct oral anticoagulants for the prevention of thromboembolic events and safety in patients with atrial fibrillation: A systematic review and meta-analysis of randomized controlled trials","name":"articletitle","label":"Article Title"},{"value":"Heart & Lung","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.hrtlng.2026.102739","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"102739"}}